Allergies & Asthma

earn free cme credit Earn CME credit by reading this article and completing the posttest. Sign Up Study Authors: Cornelia A. Verberkt, Marieke H.J. van den Beuken-van Everdingen, et al.; Eric W. Widera Target Audience and Goal Statement: Pulmonologists, pain management specialists, primary care physicians, public health and policy experts The goal of this study
0 Comments
Fixed-dose triple therapy with fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) improved lung function in adults whose asthma was uncontrolled with an inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA), the CAPTAIN study showed. On Wednesday, based on findings from the trial, the FDA approved the chronic obstructive pulmonary disease treatment at two different doses for adults 18 and
0 Comments
Specific genetic alterations in children and teens with asthma may identify those who will not benefit from treatment with the long-acting β2-adrenergic receptor agonist (LABA) salmeterol, a researcher reported. For the study, 241 children and teens (age 12-18) with asthma taking inhaled corticosteroids were randomly assigned (1:1) to receive personalized care (prescribing by rs1042713 genotype)
0 Comments
Vitamin D3 supplementation added to low-dose inhaled corticosteroids was not associated with longer time to asthma exacerbations among high-risk children with low baseline 25-hydroxyvitamin D levels, researchers reported. The mean time to exacerbation was 240 days in children randomized to the vitamin D3 supplementation group and 253 days in the placebo group (mean group difference
0 Comments
Short-term treatment with a low-dose opioid was associated with significantly improved health status in chronic obstructive pulmonary disease (COPD) patients with advanced disease and chronic breathlessness despite optimal pharmaceutical and non-pharmaceutical treatment. In a randomized trial of over 100 patients, twice daily treatment for 4 weeks with an oral sustained-release morphine (10 mg) was associated
0 Comments
As another so-called triple therapy for chronic obstructive pulmonary disease (COPD) hits the market, pulmonologists and primary care physicians are beginning to consider which patients are most appropriate for these treatments, and how much added benefit these products offer relative to more conventional — and better understood — two-drug combinations. The FDA approved AstraZeneca’s fixed-dose,
0 Comments
Inhaled triple therapy with budesonide, glycopyrrolate, and formoterol showed a signal of reducing all-cause mortality in patients with moderate to severe chronic obstructive pulmonary disease (COPD) at higher (320 μg) budesonide doses in newly reported findings from the large, multicenter, 52-week ETHOS trial. Two doses of the glucocorticoid — 160 μg and 320 μg —
0 Comments
The development of a subtype of inflammatory myopathy characterized by interstitial lung disease and positivity for a specific autoantibody was influenced by seasonality and place of residence, Japanese researchers found. Among patients with polymyositis or dermatomyositis (PM/DM) and the associated interstitial lung disease, symptom onset occurred most often from October to March for those with
0 Comments
earn free cme credit Earn CME credit by reading this article and completing the posttest. Sign Up Study Authors: Peter K. Lindenauer, Mihaela S. Stefan, et al.; Carolyn L. Rochester, Anne E. Holland Target Audience and Goal Statement: Pulmonologists, hospitalists The goal of this study was to determine the association between initiation of pulmonary rehabilitation
0 Comments
If you, like the Skeptical Cardiologist, suffer from asthma you may be wondering if you are at a higher risk of contracting COVID-19 or developing more severe respiratory complications from the disease once infected. There are 25 million asthma sufferers in the United States, about 8% of the population, and many of us are using
0 Comments
Pulmonary rehabilitation within 3 months of hospital discharge was associated with a significant reduction in deaths at 1 year in a study involving 197,376 Medicare beneficiaries hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations. Peter Lindenauer, MD, of the University of Massachusetts Medical School in Springfield, and co-researchers reported that fewer than 2% of patients
0 Comments
Exposure to synthetic endocrine-disrupting chemicals found in pesticides, nonstick cookware, and fire retardants was linked to increased risk for celiac disease in children and young adults in a small observational study. Overall, young people with higher serum concentrations of dichlorodiphenyldichloroethylene (DDE) had twice the risk for developing celiac disease (OR 2.01, 95% CI 1.07-3.78) after
0 Comments
This is the sixth story in a series by MedPage Today examining the impact of COVID-19 on vulnerable populations. Past stories reported on the homeless, immigrants in detention, the undocumented, nursing home residents, and incarcerated individuals. With limited national data available to track COVID-19 outcomes by race, states and local municipalities started releasing their own
0 Comments
With the COVID-19 pandemic, non-critical care providers are being asked to assist the critical care community in caring for COVID-19 patients. Although many healthcare systems have been able to handle the burden and ensure the “ideal” care of patients solely by critical care specialists, some systems have been overwhelmed and an “all hands on deck”
0 Comments
WASHINGTON — The FDA approved the first generic version of the Proventil HFA albuterol inhaler, citing increased demand for this type of product as a treatment for COVID-19. The metered dose inhaler, made by Cipla Ltd., delivers 90 μg albuterol sulfate per puff; the approved indication is for “treatment or prevention of bronchospasm in patients
0 Comments
Asthma is one of the most common chronic conditions in children and adults, with a prevalence of over 8% in U.S. children and 7% in adults. This translates to over 7 million children in the U.S. In 2007, the National Heart Lung and Blood Institute released “Expert Panel Report-3” for the management of asthma. These
0 Comments